Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
featured
ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

  • 112 views
  • 08 Nov, 2020
  • 1 location
featured
Celgene MDS-AML Registry Connect

Celgene MDS-AML Registry Connect

  • 38 views
  • 08 Nov, 2020
  • 1 location
Azacitidine and Homoharringtonine in JMML

, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in

refractory acute myeloid leukemia (aml)
azacitidine
myeloid leukemia
  • 0 views
  • 25 Jan, 2021
  • 1 location
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS

Acute Myeloid Leukemia (AML) patients who had achieved Complete Remission (CR) after (re)induction/consolidation chemotherapy will receive the infusion of alloreactive NK cells. Adult AML

cell transplantation
immunosuppressants
leukapheresis
cyclophosphamide
fludarabine
  • 0 views
  • 03 Feb, 2021
  • 1 location
Haplo vs. URD in AML

This study compares haplo-identical family donor stem cell transplantation (haplo SCT) to matched unrelated donor transplantation (URD SCT) in adult patients with acute myeloid leukemia (AML

graft versus host disease
mycophenolate mofetil
cell transplantation
fludarabine
cyclophosphamide
  • 4 views
  • 23 Jan, 2021
  • 14 locations
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in …

  • 0 views
  • 16 Feb, 2021
  • 1 location
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for …

allogeneic transplantation
cell transplantation
biological factors
transplant conditioning
graft versus host disease
  • 90 views
  • 23 May, 2021
  • 45 locations
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

granulocyte colony stimulating factor
colony stimulating factor
cladribine
cancer
acute leukemia
  • 0 views
  • 26 Jan, 2021
  • 1 location
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

Advances in the biological characterization of AML can now make a proper estimate of the risk of recurrence and likelihood of survival of different groups of patients according to the expression of different disease parameters. Karyotype, the molecular alterations affecting genes FLT3, NPM1 and CEBPA, minimal residual disease by flow …

residual tumor
minimal residual disease
ara-c
idarubicin
ejection fraction
  • 12 views
  • 29 Mar, 2021
  • 1 location
IFN- to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

This study proposes a safe dosing regimen IFN- that is sufficient to stimulate IFNreceptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or

  • 0 views
  • 22 Apr, 2021
  • 2 locations